Guinea

Resilience System


You are here

Science

G7 Health Ministers Propose Incentives For New Antibiotics, Commit Help On Ebola

INTELLECTUAL PROPERTY WATCH by Catherine Saez, Oct, 12, 2015

(Scroll down for Ministers' Statement.)

The health ministers of the Group of Seven (G7) most developed countries have issued a declaration on antimicrobial resistance and Ebola. The governments said they would explore innovative economic incentives to promote research and development of new antibiotics, such as a global antibiotic research fund and a market entry reward mechanism.

The G7 (Canada, France, Germany, Italy, Japan, United Kingdom, and United States) met from 8-9 October in Berlin and agreed to the Berlin Declaration [pdf] on Antimicrobial Resistance – Global Union for Antibiotics Research and Development (GUARD), aimed at supporting developing countries to develop national antimicrobial resistance action plans.

The G7 health ministers also issued a commitment on lessons learned from Ebola, and supported the 2005 World Health Organization International Health Regulations (IHR), insisting on the need to comply with them.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola Assay Card | Elisa-Based Diagnostic - Google Science Fair

submitted by Gavin Macgregor-Skinner

Temperature-Independent, Portable, and Rapid Field Detection of Ebola via a Silk-Derived Lateral-Flow System

googlesciencefair.com - 2015

I developed a “stable and stored at room temperature” Ebola Assay Card, applicable as an ELISA-based diagnostic for diseases such as HIV, Lyme and certain cancers, that will allow for water-activated, timed-release detection of Ebola antigens, with detection limits that are analogous to current sandwich ELISA techniques. Reagents become chemically “stabilized” when mixed into silk, which enables them to remain “chemically active” without refrigeration. This Ebola Assay Card will allow for shipment and storage without refrigeration, and provide detection of the Ebola viral antigens based on color change in as little as 30 minutes.

(CLICK HERE FOR ADDITIONAL INFORMATION)

 

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

How Will We Ensure the New Ebola Vaccine Reaches Those Most in Need?

HUFFINGTON POST  by Director of UNDP’s HIV, Health and Development Group, Bureau of Policy and Programme Support      Aug. 10, 2015                                                                 

 We have reasons to be optimistic about the news of a new tool in the fight against Ebola. As in the fight against HIV, science and solidarity have come together to save lives. The phase III trials on efficacy of the VSV-ZEBOV vaccine have yielded an impressive result in a relatively short time -- 100 percent effectiveness in those receiving the vaccine.

While scientists still need to figure out how long the protective effect of the vaccine lasts, and how effective it will be among the general population and with different strains of the virus, without a doubt this is an important tool for the protection of health and community workers and possibly the wider community. This will certainly help in the on-going efforts to achieve the target of zero new Ebola cases and in overall recovery efforts.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Proposed Ebola biobank would strengthen African science

NATURE by Erika Check Hayden                                                                             Aug. 10, 2015
As West Africa’s Ebola outbreak winds down, an effort is under way to make the best use of the tens of thousands of patient samples collected by public-health agencies fighting the epidemic.  Samples from the Ebola epidemic in West Africa are held by public-health agencies in the region and abroad. Daniel Berehulak/NYT/Redux/Eyevine

On 6–7 August, the World Health Organization (WHO) convened a meeting in Freetown, Sierra Leone, to discuss how to establish a biobank for up to 100,000 samples of blood, semen, urine and breast milk from confirmed and suspected Ebola patients, as well as swabs taken from the bodies of people who died from the virus. Held by health agencies in both West Africa and the West, the samples could be valuable in understanding how the current Ebola crisis evolved, preparing for future outbreaks and developing public-health research capacity in a region that depends on outside experts.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Experimental Ebola drug shelved; study explores virus clearance

CENTER FOR INFECTIOUS DISEASE POLICY AND RESEARCH by Lisa Schnirring     July 20, 2015

Tekmira Pharmaceuticals  announced that it has suspended development of TKM-Ebola, a drug cocktail that showed disappointing human trial results in West Africa, as a convalescent plasma trial at a Doctors Without Borders (MSF) facility in Guinea proceeded with no ill effects in patients so far...

In suspending TKM-Ebola development, the company said that a joint reevaluation of its contract with the US Department of Defense is under way.

In another development, MSF said a convalescent serum trial at its facility in Nongo, Guinea, has enrolled 101 people over the last few months, with no ill effects reported so far, according to a Jul 17 update on the outbreak. Patients at the Nongo treatment unit have the option to receive plasma donated by Ebola survivors....

Meanwhile, detailed testing at a Swiss hospital on a 43-year-old doctor infected with Ebola in Sierra Leone found that viral decay occurred in two phases, once starting 72 hours after symptom onset before any antiviral interventions, with acceleration in viral load decay after ZMAb infusion and oral favipiravir treatments began..

Read complete article.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Ebola outbreak help extends from space

Telemedicine and innovative devices could help reduce unnecessary exposures to virus

(Two items, scroll down.)

CANADIAN BROADCASTING CORP.                                                                                 July 19, 2015

Space technology such as satellite images and telemedicine could play a bigger role in helping to control the Ebola outbreak that's killed more than 11,250 people, a Canadian doctor says.

Canadian Space Agency astronaut Chris Hadfield holds the Microflow experiment to test how the instrument counts blood cells in orbit. Such space spinoffs have the potential to be applied to outbreaks of infectious diseases on Earth. (NASA)

This week's issue of the medical journal Lancet Infectious Disease includes a commentary titled "Help from Above — outer space and the fight against Ebola."

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Ebola genetic code analysed to show evolution of worst ever outbreak

THE GUARDIAN   by Ian Sample                                                                             June 18, 2015

Scientists have analysed the genetic code of Ebola viruses from patients across west Africa and pieced together the evolution of the worst ever outbreak of the killer disease.

Experts from Public Health England at Porton Down in Britain, the World Health Organisation (WHO), and other leading labs, used DNA from 179 Ebola samples to reconstruct the spread of the virus from Guinea into surrounding countries last year.

Problem, Solution, SitRep, or ?: 

Why Some Ebola Strains Are More Dangerous Than Others

CHEMISTRY WORLD by Christopher Barnard             June 17, 215
The virulence of Ebola virus strains appears to be innately linked to the degree of disorder in proteins that form their nucleocapsids. Computational analysis has revealed that strains responsible for the most lethal outbreaks of Ebola show significantly higher levels of intrinsic protein disorder than less virulent strains, in a discovery that could constitute a major breakthrough in understanding the pathogen’s behaviour.

With over 27,000 confirmed, probable and suspected cases and more than 11,000 fatalities worldwide, the ongoing Ebola outbreak has resulted in considerably more casualties since late 2013 than all other outbreaks combined. There are no effective treatments or vaccines against the haemorrhagic fever that evinces Ebola infection; however, strains of the virus with drastically different virulence have emerged since the first outbreak in 1976, with fatality rates ranging from 25 to 90%.

Problem, Solution, SitRep, or ?: 

Favipiravir—a prophylactic treatment for Ebola contacts?

THE LANCET byMichel Van Herp, Hilde Declerck and Tom Decroo June 13, 2015

.. the efficacy of candidate Ebola vaccines for primary prevention has not been proven.2 Furthermore, in communities in which Ebola transmission might be ongoing, an important question is: how will such a vaccination be perceived if a vaccinated person develops Ebola? Such a scenario is possible in people who contract Ebola virus before vaccination. If a person is infected with Ebola virus before vaccination, the vaccine might have a post-exposure prophylactic effect. However, how effective this prophylaxis might be is unknown.2 Moreover, if someone is infected more than 48 h before vaccination, the post-exposure prophylactic effect is likely to be insufficient, leading to possible development of Ebola after vaccination. This scenario is likely to result in serious issues relating to community trust and acceptance of an Ebola vaccine.3 How to exclude Ebola among people presenting with post-vaccination fever is also an issue.2

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

The Case for Improved Diagnostic Tools to Control Ebola Virus Disease in West Africa and How to Get There

PLOS by Arlene C. Chua,Jane Cunningham,Francis Moussy, Mark D. Perkins,and Pierre Formenty      June 11 2015

 ...Since the identification of Ebola in Guinea in March 2013, rapid deployment of international mobile laboratories through WHO networks—Global Outbreak Alert and Response Network (GOARN) [2] and Emerging and Dangerous Pathogens Laboratory Network (EDPLN) [3]—has been vital to outbreak control operations. Deployable laboratories from multiple international organizations have been established near Ebola treatment centers (ETC) in Guinea, Liberia, and Sierra Leone....

However, several technical and social factors conspire to delay diagnosis, starting with weak surveillance systems and slow patient access to centralized ETCs. While the mean processing time is 5 hours (time difference from when samples are received in the laboratory to when they are tested), there is a marked difference in the time from when the samples are collected from suspected patients to the time they are received by the laboratory

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Science
howdy folks